Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27659324 | 0.86 | RAB9A (0.43) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL11466907 | 0.84 | DEGS1 (0.56) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL466003 | 0.84 | RAB9A (0.46) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL465776 | 0.82 | RAB9A (0.47) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL17675503 | 0.82 | RAB9A (0.44) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL3720037 | 0.82 | RAB9A (0.44) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| Hydrochloric Acid SCHEMBL8722614 | 0.81 | MEN1 (0.43) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL16246036 | 0.81 | RAB9A (0.43) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL5343691 | 0.80 | RAB9A (0.47) | RAB9AMEN1KMT2AMAPTDEGS1 | |
| SCHEMBL28322047 | 0.79 | RAB9A (0.50) | RAB9AMEN1KMT2AMAPTDEGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4053108-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3774734-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | Elex Biotech, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019191502-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3468953-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2006073367-A1 | 5-THIOXO-1,5-DIHYDRO-2H-PYRROL-2-ONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1646626-A1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| EP-1646625-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005417-A1 | PYRROLE-2, 5-DIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005005416-A1 | PYRROLE-2, 5-DITHIONE DERIVATIVES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2005-01-20 | — | — | WO | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001002364-A1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | RAB9A 1888/4885MEN1 4715/4885KMT2A 3258/4885 |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | RYR2, RYR1, CACNA1F | RAB9A 1444/4885MEN1 4315/4885KMT2A 4521/4885 |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | DNMT1, DNMT3A, DNMT3B | RAB9A 1345/4885MEN1 1594/4885KMT2A 121/4885 |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | DNMT1, DNMT3A, DNMT3B | RAB9A 1345/4885MEN1 1594/4885KMT2A 121/4885 |
| US-20230183182-A1 | COMPOUND CONTAINING BENZENE RING AND APPLICATION THEREOF | P2RX4, P2RX7, P2RX2 | RAB9A 3771/4885MEN1 2798/4885KMT2A 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.